[¹⁷⁷Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer

Lancet Oncol. 2018 Aug;19(8):e371. doi: 10.1016/S1470-2045(18)30410-8.

Authors

Kambiz Rahbar¹, Hojjat Ahmadzadehfar², Robert Seifert³, Martin Boegemann⁴

Affiliations

¹ Department of Nuclear Medicine, University Hospital Muenster, 48149 Munster, Germany. Electronic address: [email protected].
² Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
³ Department of Nuclear Medicine, University Hospital Muenster, 48149 Munster, Germany.
⁴ Department of Urology, University Hospital Muenster, 48149 Munster, Germany.

PMID: 30102221
DOI: 10.1016/S1470-2045(18)30410-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Dipeptides
Heterocyclic Compounds, 1-Ring
Humans
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant*
Radioisotopes

Substances

Dipeptides
Heterocyclic Compounds, 1-Ring
PSMA-617
Radioisotopes
Prostate-Specific Antigen